stay updated with our newsletter

Close this search box.

Breakthrough Results with MCP for Prostate Cancer  

Nutrients journal logo

Prostate cancer is the second most common cause of cancer-related death in men. While there have been several diagnostic and treatment advancements in recent years, the options for men with biochemically relapsed prostate cancer (BRPC), an aggressive form of the disease, have historically been limited — until now.

According to a study published in Nutrients, a patented form of modified citrus pectin (PectaSol) provided significant benefits against prostate cancer progression and PSA doubling time (PSADT) in men with BRPC.

Results followed a group of patients with BRPC who had been taking the researched form of MCP for a total of 18 months. MCP was shown in the study to reduce prostate cancer progression, stabilize or decrease PSA, and slow PSA doubling time (PSADT) without hormonal interference or side effects.

Initially, the study enrolled 59 prostate cancer patients from leading oncology centers in Israel. Participants took 4.8 grams of MCP 3 times/day. After 6 months, 46 subjects (78%) showed response to MCP, with decreased or stabilized PSA in 34 subjects (58%). 44 subjects (75%) showed improvement of PSADT with negative scans. These early 6-month results were published in Nutrients in 2021.

For the study’s final arm, 46 of 59 subjects could continue for 12 more months. Seven subjects dropped from the study and purchased MCP independently, with steady benefits. The remaining 39 subjects continued for an additional 12 months, for a total of 18 months.

Final 18-month results demonstrated that: 

  • 90% of the subjects had improvement or stabilization of PSADT
  • 62% had decreased or stable PSA
  • 85% had no disease progression, biochemically and in scans

No toxicity or side effects were observed. These results were presented at the American Society of Clinical Oncology Genitourinary Symposium in February 2023 and then published in Nutrients.

This long-term clinical trial is a landmark study because it highlights the robust benefits and safety of a non-hormonal treatment (MCP) in the management of aggressive prostate cancer. Therapeutic options for this patient population are limited, and hormonal interventions carry major risks that can shorten the window of time for treatment viability. This study adds to the evidence of MCP as an effective alternative to high-risk hormonal interventions.

With 80+ published studies, PectaSol MCP, the original and only researched form of MCP, is becoming one of the most-studied dietary supplements demonstrating clinically relevant benefits for today’s most critical areas of health, including oncology, cardiovascular and kidney health, and others.



Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.